VIDEO: Amivantamab plus lazertinib improved PFS vs. osimertinib in EGFR-mutated NSCLC
Click Here to Manage Email Alerts
MADRID — In this video interview with Healio, Hossein Borghaei, DO, MS, talked about results from the MARIPOSA study presented at ESMO Congress.
The study evaluated amivantamab (Rybrevant, Janssen) plus lazertinib (Leclaza; Yuhan, Janssen) vs. osimertinib (Tagrisso, AstraZeneca) as first-line treatment in EGFR-mutated advanced non-small cell lung cancer.
The results showed a median PFS of 23.7 months with amivantamab plus lazertinib vs. a median PFS around 16.6 months with osimertinib, according to Borghaei, chief of the division of thoracic medical oncology at Fox Chase Cancer Center.
“The hazard ratio here is 0.7, so a 30% reduction in the PFS. This was statistically significant, so the combination was a little bit better than [osimertinib] alone.
“I think it’s a little too soon to have overall survival, but the interim was reported at the meeting. I’m sure at the subsequent meetings we’re going to have more information,” he added.
Reference:
- Cho BC, et al. Abstract LBA14. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Healio Interviews
Click Here to Manage Email Alerts